Literature DB >> 33903113

Melting the eis: Nondetection of Kanamycin Resistance Markers by Routine Diagnostic Tests and Identification of New eis Promoter Variants.

Serej D Ley1,2,3, Samantha Pillay3,4, Elizabeth M Streicher3, Yuri F van der Heijden5,6,7, Frederik Sirgel3, Brigitta Derendinger3, Marianna de Kock3, Sébastien Gagneux1,2, Robin M Warren3, Grant Theron3, Margaretha de Vos3.   

Abstract

Eis promoter mutations can confer reduced Mycobacterium tuberculosis kanamycin susceptibility. GenoType MTBDRsl, a widely used assay evaluating this region, wrongly classified 17/410 isolates as eis promoter wild type. Six out of seventeen isolates harbored mutations known to confer kanamycin resistance, and the remainder harbored either novel eis promoter mutations (7/11) or disputed mutations (4/11). GenoType MTBDRsl can miss established and new variants that cause reduced susceptibility. These data highlight the importance of reflex phenotypic kanamycin testing.

Entities:  

Keywords:  Mycobacterium tuberculosis; extensive drug resistance; second-line injectables

Mesh：

Substances：

Year:  2021        PMID： 33903113      PMCID： PMC8218670          DOI： 10.1128/AAC.02502-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  20 in total

1.  The role of eis mutations in the development of kanamycin resistance in Mycobacterium tuberculosis isolates from the Moscow region.

Authors:  Marina B Gikalo; Elena Y Nosova; Ludmila Y Krylova; Arkadyi M Moroz
Journal:  J Antimicrob Chemother       Date:  2012-05-16       Impact factor: 5.790

2.  Overexpression of the chromosomally encoded aminoglycoside acetyltransferase eis confers kanamycin resistance in Mycobacterium tuberculosis.

Authors:  M Analise Zaunbrecher; R David Sikes; Beverly Metchock; Thomas M Shinnick; James E Posey
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-11       Impact factor: 11.205

3.  Correlating rrs and eis promoter mutations in clinical isolates of Mycobacterium tuberculosis with phenotypic susceptibility levels to the second-line injectables.

Authors:  Priti Kambli; Kanchan Ajbani; Chaitali Nikam; Meeta Sadani; Anjali Shetty; Zarir Udwadia; Sophia B Georghiou; Timothy C Rodwell; Antonino Catanzaro; Camilla Rodrigues
Journal:  Int J Mycobacteriol       Date:  2015-10-01

4.  Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes.

Authors:  G Canetti; W Fox; A Khomenko; H T Mahler; N K Menon; D A Mitchison; N Rist; N A Smelev
Journal:  Bull World Health Organ       Date:  1969       Impact factor: 9.408

5.  Minority Mycobacterium tuberculosis Genotypic Populations as an Indicator of Subsequent Phenotypic Resistance.

Authors:  David M Engelthaler; Elizabeth M Streicher; Erin J Kelley; Christopher J Allender; Kristin Wiggins; Dulce Jimenez; Darrin Lemmer; Eric Vittinghoff; Grant Theron; Frederick A Sirgel; Robin M Warren; John Z Metcalfe
Journal:  Am J Respir Cell Mol Biol       Date:  2019-12       Impact factor: 6.914

6.  Quantitative drug susceptibility testing of Mycobacterium tuberculosis by use of MGIT 960 and EpiCenter instrumentation.

Authors:  Burkhard Springer; Katja Lucke; Romana Calligaris-Maibach; Claudia Ritter; Erik C Böttger
Journal:  J Clin Microbiol       Date:  2009-04-01       Impact factor: 5.948

7.  A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis.

Authors:  Paolo Miotto; Belay Tessema; Elisa Tagliani; Leonid Chindelevitch; Angela M Starks; Claudia Emerson; Debra Hanna; Peter S Kim; Richard Liwski; Matteo Zignol; Christopher Gilpin; Stefan Niemann; Claudia M Denkinger; Joy Fleming; Robin M Warren; Derrick Crook; James Posey; Sebastien Gagneux; Sven Hoffner; Camilla Rodrigues; Iñaki Comas; David M Engelthaler; Megan Murray; David Alland; Leen Rigouts; Christoph Lange; Keertan Dheda; Rumina Hasan; Uma Devi K Ranganathan; Ruth McNerney; Matthew Ezewudo; Daniela M Cirillo; Marco Schito; Claudio U Köser; Timothy C Rodwell
Journal:  Eur Respir J       Date:  2017-12-28       Impact factor: 16.671

8.  Population-level emergence of bedaquiline and clofazimine resistance-associated variants among patients with drug-resistant tuberculosis in southern Africa: a phenotypic and phylogenetic analysis.

Authors:  Camus Nimmo; James Millard; Lucy van Dorp; Kayleen Brien; Sashen Moodley; Allison Wolf; Alison D Grant; Nesri Padayatchi; Alexander S Pym; François Balloux; Max O'Donnell
Journal:  Lancet Microbe       Date:  2020-08

9.  Whole genome sequencing reveals genomic heterogeneity and antibiotic purification in Mycobacterium tuberculosis isolates.

Authors:  P A Black; M de Vos; G E Louw; R G van der Merwe; A Dippenaar; E M Streicher; A M Abdallah; S L Sampson; T C Victor; T Dolby; J A Simpson; P D van Helden; R M Warren; A Pain
Journal:  BMC Genomics       Date:  2015-10-24       Impact factor: 3.969

10.  Integrating standardized whole genome sequence analysis with a global Mycobacterium tuberculosis antibiotic resistance knowledgebase.

Authors:  Matthew Ezewudo; Amanda Borens; Álvaro Chiner-Oms; Paolo Miotto; Leonid Chindelevitch; Angela M Starks; Debra Hanna; Richard Liwski; Matteo Zignol; Christopher Gilpin; Stefan Niemann; Thomas Andreas Kohl; Robin M Warren; Derrick Crook; Sebastien Gagneux; Sven Hoffner; Camilla Rodrigues; Iñaki Comas; David M Engelthaler; David Alland; Leen Rigouts; Christoph Lange; Keertan Dheda; Rumina Hasan; Ruth McNerney; Daniela M Cirillo; Marco Schito; Timothy C Rodwell; James Posey
Journal:  Sci Rep       Date:  2018-10-18       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.